Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is a 6-week, double-blind, randomized, placebo-controlled, multicenter, parallel group
Phase 3 study of NAFT-600 applied once a day for 2 weeks compared to vehicle (placebo) in the
treatment of tinea pedis.
Phase:
Phase 3
Details
Lead Sponsor:
Merz North America, Inc. Merz Pharmaceuticals, LLC